CYT-0851 Plus Capecitabine Demonstrates Efficacy in Advanced Ovarian Cancer
The combination of the novel MCT inhibitor CYT-0851 and capecitabine displayed clinical activity and a tolerable safety profile in patients with advanced platinum-resistant ovarian cancer.
Source: onclive.com